---
title: "Brii Biosciences says arbitration with Vir clouds future of elebsiran program"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291596618.md"
description: "Brii Biosciences announced an ongoing arbitration with Vir Biotechnology, creating uncertainty regarding the future of its elebsiran hepatitis B program. The dispute currently blocks investment in any Phase 3 studies using elebsiran until the claims are resolved. Brii stated it will monitor developments and assess the implications for the program's viability."
datetime: "2026-07-02T22:56:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291596618.md)
  - [en](https://longbridge.com/en/news/291596618.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291596618.md)
---

# Brii Biosciences says arbitration with Vir clouds future of elebsiran program

-   Brii flagged ongoing arbitration with Vir Biotechnology that has made the future of its elebsiran hepatitis B program uncertain. \* The dispute blocks investment in any Phase 3 study using elebsiran until the claims are resolved. \* The company said it will monitor developments and assess implications for the program’s viability. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brii Biosciences Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260703-12230311), on July 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [02137.HK](https://longbridge.com/en/quote/02137.HK.md)
- [VIR.US](https://longbridge.com/en/quote/VIR.US.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [Analyst Reiterates Buy on Vir Biotechnology, Citing Advancing Hepatitis D and Oncology Pipelines and Strong Cash Runway](https://longbridge.com/en/news/295091535.md)
- [Brii Biosciences schedules board meeting to review interim results](https://longbridge.com/en/news/295249467.md)
- [What Vir Biotechnology (VIR)'s Profit Swing But Earnings Miss Means For Shareholders](https://longbridge.com/en/news/295294866.md)
- [Vir Biotechnology names Brent Sabatini interim principal financial officer as CFO exits](https://longbridge.com/en/news/293757111.md)
- [VIR: Q2 2026 net income reached $80.1M, fueled by Astellas collaboration and clinical progress](https://longbridge.com/en/news/295009433.md)